

Date of issue: 06-FEB-2015 Replaces version of: 09-JUN-2010 TEKAMLO FCT 150/5MG 7 (SA-BOTTLE) 719804 (US02)

1. Identification of the substance/preparation and of the company

Product name Generic Name Pharmacological Actior	TEKAMLO FCT 150/5MG 7 (SA-BOTTLE) ALISKIREN HEMIFUMARATE, Amlodipine besylate Renin inhibitor, antihypertensive agent
Usage	Drug product (pharmaceutical bulk, primary packed, finished product, pharmaceutical intermediate)
Company name	Novartis Pharma AG 4002 Basel Switzerland Tel: +41 61 324 11 11, email: sds.support@novartis.com
Emergency phone number	CHEMTEL (International) +1 813 676 1670

2. Hazards identification

For side effects, which could also have impact for people working with this substance, please refer to the Patient Information Leaflet.

3. Composition / information on ingredients

For classification of declared components, see section 15, "Regulatory Information"

Chemical Name	Contains:	CAS Number
ALISKIREN HEMIFUMARATE	approx. 33 %	173334-58-2
Amlodipine besylate	0.5 - 3 %	111470-99-6

Remaining components are inert ingredients.

For TLV values of declared components, see Section 8, Exposure controls / Personal

4. First aid measures

Eye Contact	Immediately rinse eyes thoroughly with running water as long as possible (approx. 15 min). Take injured quickly to factory medical center or call an ambulance (code word: eye accident).
Skin Contact	Remove contaminated clothing. Rinse contaminated skin immediately with plenty of water and soap and seek medical advice.
Inhalation	Remove the victim from danger zone, avoid further exposure.
Ingestion	If swallowed, seek medical advice immediately and show this container or label.
Notes to Physician	General measures to eliminate the substance and to reduce absorption.

5. Fire fighting measures

Suitable Extinguishing Media	Water spray or fog, foam, dry chemical powder, CO2, dry sand
Unsuitable Extinguishing Media	No restrictions
Protective equipment for firefighters	Wear self-contained breathing apparatus and fire protective suite.

6. Accidental release measures

Personal precautions	Avoid contact with skin, eyes and clothing.
Environmental precautions	Must not be released into sewers, drains or wells.
Methods for cleaning	Transfer large quantities into a container. Clean up the rest with absorbent material and



Date of issue: 06-FEB-2015 Replaces version of: 09-JUN-2010 TEKAMLO FCT 150/5MG 7 (SA-BOTTLE) 719804 (US02)

discharge properly.

7. Handling and storage

No special handling requirements for normal use of this material. Store in a dry and cool place and observe special instructions from supplier.

8. Exposure controls / Personal protection

Occupational Exposure Limit (OEL)			
no data available			
TLV values of declared components Contains: ALISKIREN HEMIFUMARATE			
List type	μg/m3		
Internal exposure limit	150	 	
Contains: Amlodipine besylate			
List type	μg/m3		
Internal exposure limit	17	 	
Personal protection for open handling			
Health care personnel	Safety glasses (EN166) La (EN374)	Safety glasses (EN166) Lab coat Disposable gloves (EN374)	

9. Physical and chemical properties

FormulationTabletFlash Pointnot available

10. Stability and reactivity

Under the normal conditions of use, the product is stable.

11. Toxicological information

Acute Toxicity

Data of ALISKIREN HEMIFUMARATE LD50: approx. 1000 mg/kg Route: oral Species: rat Data of Amlodipine besylate LD50: 393 mg/kg Route: oral Species: rat Data of Amlodipine besylate LD50: 686 mg/kg Route: oral Species: rat, Sex: female Data of Amlodipine besylate LD50: 37 mg/kg Route: oral

Date of issue: 06-FEB-2015 Replaces version of: 09-JUN-2010 TEKAMLO FCT 150/5MG 7 (SA-BOTTLE) 719804 (US02)

Irritation, Corrosion	Species: mouse Data of Amlodipine besylate TDLo: 40 mg/kg Route: oral Species: rat Data of Amlodipine besylate LDLo: 10 mg/kg Route: oral Species: dog Values of ALISKIREN HEMIFUMARATE The substance has an irritating potential. Data of ALISKIREN HEMIFUMARATE Respiratory system (Species: rat) corrosive See comment. Data of ALISKIREN HEMIFUMARATE Skin (Species: mouse) irritant
	Method: Assessment of contact allergenic potential with the murine local lymph node assay (LLNA TIER II) Data of Amlodipine besylate Eyes (Species: rabbit) strongly corrosive
	Free base Skin (Species: rabbit) non irritant Free base
Sensitisation	Data of ALISKIREN HEMIFUMARATE Skin (Species: mouse) not sensitizing Method: Assessment of contact allergenic potential with the murine local lymph node assay (LLNA TIER II)
	Data of Amlodipine besylate Skin (Species: guinea pig) not sensitizing Method: OECD 406 * 1981 * Guinea pig maximisation test
Additional advice	Data of ALISKIREN HEMIFUMARATE The compound is a local irritant of the upper respiratory tract and can cause inflammation and necrosis of the respiratory epithelium. Data of ALISKIREN HEMIFUMARATE Not mutagenic in AMES Test. Data of Amlodipine besylate Handling this substance, precautionary measures should be taken according to workplace health risk assessment.
Mutagenicity	Data of ALISKIREN HEMIFUMARATE Negative (AMES-Test (reverse mutation assay)) in vitroCell: Strains of salmonella typhimurium.
	Data of ALISKIREN HEMIFUMARATE Negative (Chromosome Aberration Study) in vitroCell: Chinese hamster ovary (CHO) cells
	Data of ALISKIREN HEMIFUMARATE Negative (Micronucleus Test) in vivo, Species: rat, Cell: Bone marrow
	Data of Amlodipine besylate Negative (in vitro) Cell: Mammalian HeLa 83 cells
	Data of Amlodipine besylate Negative with and without metabolic activation (AMES-Test (reverse mutation assay)) in vitroCell: Strains of salmonella typhimurium.
	Data of Amlodipine besylate Negative



Date of issue: 06-FEB-2015 Replaces version of: 09-JUN-2010 TEKAMLO FCT 150/5MG 7 (SA-BOTTLE) 719804 (US02)



	in vitroCell: Lymphoma cells L5178Y of the mouse Data of Amlodipine besylate Negative (Chromosome Aberration Study)
	in vitro
	Data of Amlodipine besylate Negative (DNA Damage and Repair, Unscheduled DNA Synthesis in vivo) in vivo
Chronic Effects	Data of ALISKIREN HEMIFUMARATE Upper respiratory tract inflammation and necrosis. (Repeated Dose Toxicity (subchronic study)) NOAEL: = 50 mg/kg/d LOEL: 150 mg/kg/d Route: oral
	Species: rat Dosage: <= 600 mg/kg/d, Duration: 26 weeks
	Data of ALISKIREN HEMIFUMARATE Pathological findings (Repeated Dose Toxicity (subacute study)) NOAEL: 2 mg/kg/d
	Route: oral Species: Marmoset, Organ: Kidneys Dosage: <= 20 mg/kg/d, Duration: 39 weeks
	Data of ALISKIREN HEMIFUMARATE No findings (Carcinogenesis)
	NOEL: 250 mg/kg/d Route: oral
	Species: Transgenic mouse Dosage: <= 1500 mg/kg/d, Duration: 6 months
	Data of Amlodipine besylate (Repeated Dose Toxicity) Route: oral
	Species: rat, Organ: Blood Duration: 26 weeks
	Data of Amlodipine besylate (Repeated Dose Toxicity) LOAEL: 3.75 mg/kg/d
	Route: oral Species: dog Duration: 13 weeks
	Data of Amlodipine besylate (Repeated Dose Toxicity) NOAEL: 3 mg/kg/d
	Route: oral Species: rat Dosage: 2.5 mg/kg/d, Duration: 13 weeks
	Data of Amlodipine besylate No evidence for carcinogenicity (Repeated Dose Toxicity) NOAEL: 0.5 mg/kg/d Route: oral
	Species: rat Duration: 2 years
	Data of Amlodipine besylate (Repeated Dose Toxicity) NOAEL: 2 mg/kg/d Route: oral
	Species: rat Duration: 52 weeks
	Duration: 52 weeks Data of Amlodipine besylate No evidence for carcinogenicity (Repeated Dose Toxicity) NOAEL: 0.5 mg/kg/d



Date of issue: 06-FEB-2015 Replaces version of: 09-JUN-2010 TEKAMLO FCT 150/5MG 7 (SA-BOTTLE) 719804 (US02)

Reproduction Toxicity	Route: oral Species: mouse Duration: 2 years Values of ALISKIREN HEMIFUMARATE This substance has been shown to have unwanted effects during the second and third trimesters of pregnancy and/or unborn/offspring. It is recommended that pregnant women working with or around this substance are informed and their exposure evaluated according to local policies. Handling this substance, precautionary measures should be taken according to workplace health risk assessment. Values of Amlodipine besylate The substance may have unwanted effects on the reproductive system of both sexes. This substance may have unwanted effects on pregnancy and/or unborn/offspring. It is recommended that pregnant women working with or around this substance are informed and their exposure evaluated according to local policies. Handling this substance, precautionary measures should be taken according to workplace health risk assessment.
	Data of Amlodipine besylate Maternal toxicity (Segment II (Embryotoxicity/fetotoxicity and teratogenicity)) NOAEL: 10 mg/kg/d Route: oral Species: rat
	Data of Amlodipine besylate Fetal toxicity (Segment II (Embryotoxicity/fetotoxicity and teratogenicity)) NOAEL: 25 mg/kg/d Route: oral Species: rat
	Data of Amlodipine besylate Maternal toxicity (Segment II (Embryotoxicity/fetotoxicity and teratogenicity)) NOAEL: 4 mg/kg/d Route: oral Species: rabbit
	Data of Amlodipine besylate Not teratogenic / not embryotoxic (Segment I (Fertility toxicity)) NOAEL: 2 mg/kg/d Route: oral Species: rat
	Data of Amlodipine besylate Negative (Segment I (Fertility toxicity)) Route: oral Species: rat, Sex: male
	Data of Amlodipine besylate Negative (Segment I (Fertility toxicity)) Route: oral Species: rat, Sex: male
	Data of Amlodipine besylate Increased pre-implantation loss (Segment II (Embryotoxicity/fetotoxicity and teratogenicity)) NOAEL: 2 mg/kg/d Route: oral Species: mouse, Sex: male
	Data of Amlodipine besylate Not teratogenic / not embryotoxic (Segment II (Embryotoxicity/fetotoxicity and teratogenicity)) NOAEL: 25 mg/kg/d Route: oral Species: rat
	Data of Amlodipine besylate Fetal toxicity (Segment II (Embryotoxicity/fetotoxicity and teratogenicity)) NOAEL: 25 mg/kg/d Route: oral Species: rabbit



Date of issue: 06-FEB-2015 Replaces version of: 09-JUN-2010 TEKAMLO FCT 150/5MG 7 (SA-BOTTLE) 719804 (US02)

> Data of Amlodipine besylate Not teratogenic / not embryotoxic (Segment II (Embryotoxicity/fetotoxicity and teratogenicity)) NOAEL: 25 mg/kg/d Route: oral Species: rabbit Data of Amlodipine besylate Maternal toxicity (Segment III (Peri- and postnatal toxicity)) NOAEL: 4 mg/kg/d Route: oral Species: rat

12. Ecological information

Biological Elimination	Data of ALISKIREN HEMIFUMARATE Degradation: 5 % (aerobic: Temperature: 22 °C DOC) Not readily degradable Initial conc.: 40 mg/l, Duration: 28 days Method: 92/69/EC (L383) C.4-A * Dissolved organic carbon (DOC) die-away Inhibitory effects can be excluded.
Fish acute toxicity	Data of ALISKIREN HEMIFUMARATE LC50: > 100 mg/l NOEC: >= 100 mg/l Species: zebra fish (danio rerio) Exp. time: 96 hours Method: 92/69/EEC (L383) C.1 * Acute toxicity for fish
Fish chronic toxicity	Data of ALISKIREN HEMIFUMARATE NOEC: 10.6 mg/l Species: fathead minnow (pimephales promelas) Exp. time: 31 days Method: OECD 210 * 1992
	Data of Amlodipine besylate LOEC: 4.6 mg/l NOEC: NOEC: 2.2 mg/l Species: fathead minnow (pimephales promelas) Exp. time: 31 days Method: OECD 210 * 1992
Aquatic invertebrate acute toxicity	Data of ALISKIREN HEMIFUMARATE EC50: 56 mg/l NOEC: 30 mg/l EC100: > 100 mg/l Species: daphnia magna (water flea) Exp. time: 48 hours Method: 92/69/EEC (L383) C.2 * Acute toxicity for daphnia
	Data of Amlodipine besylate EC50: 3.2 mg/l Species: daphnia magna (water flea) Exp. time: 48 hours
Aquatic invertebrate chronic toxicity	Data of ALISKIREN HEMIFUMARATE NOEC: 10 mg/l Species: daphnia magna (water flea) Exp. time: 21 days Method: OECD 211 * 2008
	Data of Amlodipine besylate EC50: 0.58 mg/l NOEC: 0.22 mg/l Species: daphnia magna (water flea) Exp. time: 21 days Method: OECD 211 * 2008



Date of issue: 06-FEB-2015 Replaces version of: 09-JUN-2010 TEKAMLO FCT 150/5MG 7 (SA-BOTTLE) 719804 (US02)

Algae Toxicity	Data of ALISKIREN HEMIFUMARATE EbC50: > 100 mg/l ErC50: > 100 mg/l NOEC: 100 mg/l Species: Desmodesmus subspicatus/Scenedesmus subspicatus (Green algae) Exp. time: 72 hours Method: 92/69/EC (L383) C.3
	Data of Amlodipine besylate ErC50: 0.23 mg/l EbC50: 0.11 mg/l NOEC: 0.029 mg/l Species: Green algae - fresh water (Pseudokirchneriella subcapitata) Exp. time: 72 hours Method: OECD 201 * 2006 * Growth inhibition; ISO 8692 * 2004
Bacterial Respiration Inhibition	Data of ALISKIREN HEMIFUMARATE EC50: 4470 mg/l Species: activated sludge Exp. time: 3 hours Method: Inhibition of Oxygen Consumption by activated sludge (87/302/EEC), Part C Data of Amlodipine besylate NOEC: 10 mg/l LOEC: 32 mg/l Species: activated sludge Exp. time: 3 hours Method: OECD 209 * 1984
Ecotoxicity Summary	Data of ALISKIREN HEMIFUMARATE Avoid release to the environment. Data of Amlodipine besylate No quantifiable data available. Data of Amlodipine besylate Toxic to aquatic organisms. Data of Amlodipine besylate Avoid release to the environment.

13. Disposal considerations

Disposal Requirements Fill into suitable waste receptacles, seal and label them properly. Incineration in an approved, controlled furnace with combustion gas scrubbing and emission gas control. Local regulations should be adhered to.

14. Transport information

Regulation	Class	UN No.	PG	Label	LQ	
RID/ADR:	not restricted	0			N.A.	
IMDG-Code:	not restricted	0				
ICAO/IATA-DGR:	not restricted	0				

ICAO/IATA-DGR: no dangerous good Proper shipping name: -

15. Regulatory information

Classifications of components:

Chemical Name	Contains:	CAS Number	Picto	Signal Word	Classification
ALISKIREN HEMIFUMARATE approx. 33 %		173334-58		W	H302, H361d, H335,



Date of issue: 06-FEB-2015 Replaces version of: 09-JUN-2010 TEKAMLO FCT 150/5MG 7 (SA-BOTTLE) 719804 (US02)

		2		H373, H402
Amlodipine besylate	0.5 - 3 %	111470-99- 6 🚯 🏠 🏠	D	H302, H318, H373, H400, H410

Remaining components are inert ingredients.

16. Other information

Abbreviations used

H302: Harmful if swallowed.

H335: May cause respiratory irritation.

H361d: Suspected of damaging the unborn child.

H373: May cause damage to organs through prolonged or repeated exposure.

H402: Harmful to aquatic life. (in EU not leading to classification as hazardous)

H318: Causes serious eye damage.

H400: Very toxic to aquatic life.

H410: Very toxic to aquatic life with long lasting effects.

Recipient

Henry Delima Delima Associates 1227 Providence Terr McLean, VA USA

Product should be stored, handled and used in accordance with good industrial hygiene practices and in conformity with legal regulations. The information contained herein is based on the present state of our knowledge and is intended to describe our products from the point of view of safety requirements. It should therefore not be construed as guaranteeing specific properties.